Versant Ventures
Versant Ventures caters to the healthcare sector with early and later stage venture, private equity, and debt financing investments.
Business Model:
Revenue: $6M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Versant Ventures Information
Geographic Data
Address: One Sansome Street
City: San Francisco
State: CA
Zip: 94104
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
3,552,464Website Global Rank
3,632Website Monthly Traffic
Twitter Followers
Description
Versant Ventures is a healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $2.3 billion under management and offices in Canada, the U.S., and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 65 Versant companies have achieved successful acquisitions or IPOs.
Contact Phone:
+14158018100
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2012 | Minerva Surgical | Venture Round | 20M |
| 3/2004 | Jazz Pharmaceuticals | Series B | 0 |
| 3/2013 | Achaogen | Series D | 18.9M |
| 9/2011 | Kythera Biopharmaceuticals | Series D | 0 |
| 5/2015 | NeuWave Medical | Series C | 25.3M |
| 11/2006 | Amira Pharmaceuticals | Series A | 4M |
| 8/2002 | Concuity | Series C | 16.3M |
| 8/2010 | Respicardia | Series C | 0 |
| 10/2015 | Audentes Therapeutics | Series C | 65M |
| 3/2009 | Inogen | Series E | 3M |
| 6/2004 | Ablation Frontiers | Series A | 3.6M |
| 10/2018 | Gotham Therapeutics | Series A | 54M |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 5/2016 | Nouscom | Series A | 13.6M |
| 2/2006 | Ablation Frontiers | Series B | 15.1M |
| 6/2013 | ForSight Labs | Series B | 9.3M |
| 4/2005 | ParAllele Bioscience | Convertible Note | 6M |
| 7/2008 | Hicuity Health | Series B | 5M |
| 1/2022 | Nested Therapeutics | Seed Round | 35M |
| 1/2001 | Cameron Health | Series A | - |
| 3/2009 | NovaLign Orthopaedics | Series B | 10M |
| 5/2012 | NeoVista | Venture Round | 6M |
| 1/2006 | Ambrx | Series B | 5M |
| 7/2006 | GluMetrics | Series B | 9M |
| 11/2017 | Nouscom | Series B | 48.8M |
| 5/2014 | Ceterix Orthopaedics | Series B | 18M |
| 12/2012 | Flexion Therapeutics | Series B | 20M |
| 7/2019 | Century Therapeutics | Series A | 250M |
| 8/2022 | Vector BioPharma | Series A | 0 |
| 1/2014 | Intuity Medical | Venture Round | 5.5M |
| 10/2008 | Lutonix | Series B | 20M |
| 9/2003 | NovaCardia | Venture Round | 22M |
| 10/2013 | Inceptus | Series A | 4.7M |
| 3/2012 | Sequent Medical | Series C | 26M |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 12/2005 | Acclarent | Series B | 25M |
| 5/2004 | NeoVista | Series A | 2M |
| 11/2012 | CardiAQ Valve Technologies | Series B | 37.3M |
| 7/2005 | Nanoplex Technologies | Series B | 2.5M |
| 2/2013 | Nuvaira | Series C | 10M |
| 1/2018 | Intuity Medical | Venture Round | 0 |
| 11/2016 | Intuity Medical | Venture Round | 0 |
| 7/2006 | ROX Medical | Series B | 10.1M |
| 6/2008 | ROX Medical | Series C | 33M |
| 10/2013 | Inari Medical | Series A | 4.7M |
| 9/2021 | 858 Therapeutics | Series A | 0 |
| 12/2008 | Hotspur Technologies | Series A | 1.3M |
| 7/2005 | Integrated Diagnostics | Series A | - |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 6/2018 | Akero Therapeutics | Series A | 65M |
| 3/2005 | Ambrx | Series A | 23.4M |
| 3/2014 | PIQUR Therapeutics | Series A | 32M |
| 1/2001 | Salmedix | Series A | - |
| 11/2006 | Intersection Medical Inc | Series B | 5M |
| 8/2011 | Intuity Medical | Series D | 12M |
| 9/2015 | Veran Medical Technologies | Venture Round | 0 |
| 9/2014 | Ivantis | Series B | 25M |
| 2/2021 | Vividion Therapeutics | Series C | 135M |
| 11/2004 | Accelerator Corp. | Venture Round | 0 |
| 11/2009 | CymaBay Therapeutics | Series E | 0 |
| 1/2009 | Synosia Therapeutics | Series B | 0 |
| 1/2009 | AlterG | Series B | 8M |
| 11/2015 | Crinetics Pharmaceuticals | Series A | 40M |
| 4/2012 | Five Prime Therapeutics | Private Equity Round | 10M |
| 1/2016 | Benvenue Medical | Equity | 23M |
| 1/2010 | The Foundry | Series A | 3M |
| 10/2011 | Realeve | Series C | 32M |
| 6/2013 | Veracyte | Series C | 28M |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 10/2009 | Flexion Therapeutics | Series A | 33M |
| 8/2001 | Insulet | Series B | 11M |
| 9/2002 | Alexza Pharmaceuticals | Series A | 0 |
| 2/2019 | Nuvaira | Equity | 79M |
| 1/2018 | Pandion Therapeutics | Series A | 58M |
| 11/2002 | Skylight Healthcare Systems | Series B | 7.8M |
| 11/2003 | NeoGuide Systems | Series B | 0 |
| 1/2017 | Halio | Series C | 65M |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 12/2017 | Respicardia | Venture Round | 0 |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 1/2017 | Therachon | Series A | 5M |
| 8/2020 | T-knife | Series A | 78.4M |
| 4/2014 | AAVLife | Series A | 12M |
| 9/2019 | Repare Therapeutics | Series B | 82.5M |
| 9/2021 | iECURE | Series A | 50M |
| 7/2013 | Audentes Therapeutics | Series A | 30M |
| 8/2018 | Therachon | Series B | 60M |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 6/2015 | Sebacia | Series C | 12M |
| 4/2014 | Sequent Medical | Series D | 20M |
| 8/2006 | ImpediMed | Venture Round | 3.4M |
| 4/2011 | Halscion, Inc. | Venture Round | 3.5M |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 4/2007 | NovaCardia | Series B | 18M |
| 7/2004 | LipoSonix | Series C | 27M |
| 10/2013 | Immune Design | Series C | 49M |
| 7/2006 | Ambrx | Series C | 52M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 9/2019 | Passage Bio | Series B | 110M |
| 6/2009 | Nexis Vision | Series B | 12M |
| 8/2008 | Glaukos | Series D | 35M |
| 10/2004 | Concuity | Venture Round | 8.3M |
| 8/2021 | Jnana Therapeutics | Series B | 50M |
| 12/2000 | Skylight Healthcare Systems | Series A | - |
| 11/2017 | Oyster Point Pharmaceuticals | Series A | 22M |
| 1/2018 | Aligos Therapeutics | Series A | 100M |
| 6/2002 | Spiration | Series D | 22M |
| 11/2006 | Neurotech | Series B | 0 |
| 9/2015 | Therachon | Series A | 35M |
| 1/2020 | VectivBio | Series A | 35M |
| 12/2022 | Launchpad Therapeutics | Series A | 0 |
| 10/2020 | RayzeBio | Series A | 45M |
| 7/2020 | Bright Peak Therapeutics | Series A | 35M |
| 10/2015 | Turnstone Biologics | Series A | 11.3M |
| 7/2015 | PIQUR Therapeutics | Series A | 19M |
| 9/2009 | Helicos BioSciences | Post-IPO Equity | 10M |
| 1/2008 | Inogen | Series E | 12.7M |
| 9/2012 | Rox Medical | Series D | 6M |
| 8/2012 | AlterG | Series C | 10M |
| 10/2009 | SpaceOAR | Series B | 6.1M |
| 11/2006 | Impedance Cardiology Systems | Series B | 5M |
| 12/2021 | CODA Biotherapeutics | Venture Round | 0 |
| 5/2008 | Kythera Biopharmaceuticals | Series C | 0 |
| 10/2010 | Synosia Therapeutics | Series C | 0 |
| 1/2007 | Synosia Therapeutics | Venture Round | 32.5M |
| 2/2007 | Trius Therapeutics | Series A | 20M |
| 12/2014 | Audentes Therapeutics | Series B | 42.5M |
| 4/2014 | RedBrick Health | Venture Round | 7.5M |
| 11/2022 | Jnana Therapeutics | Series C | 0 |
| 1/2007 | Calypso Medical | Series D | 42.2M |
| 2/2015 | Laguna Pharmaceuticals | Series B | 30M |
| 3/2021 | Century Therapeutics | Series C | 0 |
| 4/2020 | Pandion Therapeutics | Series B | 80M |
| 4/2018 | Enterprise Therapeutics | Series B | 41.3M |
| 1/2017 | Ebb Therapeutics | Series B | 0 |
| 6/2017 | Repare Therapeutics | Series A | 68M |
| 2/2007 | Inogen | Series D | 22M |
| 11/2021 | ViaLase | Series A | 27.3M |
| 2/2006 | Amphora Discovery | Series E | 4.4M |
| 7/2006 | Kythera Biopharmaceuticals | Series B | 30M |
| 2/2017 | Vividion Therapeutics | Series A | 50M |
| 2/2008 | PhaseRx | Series A | 20.2M |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 3/2018 | Inari Medical | Series C | 20.9M |
| 2/2019 | Oyster Point Pharmaceuticals | Series B | 0 |
| 3/2008 | Spiration | Series G | 18.5M |
| 2/2007 | Vantage Oncology | Series D | 0 |
| 12/2001 | Pharmion | Venture Round | 65M |
| 5/2014 | Anokion | Series A | 37.5M |
| 11/2022 | iECURE | Series A | 0 |
| 8/2021 | T-knife | Series B | 110M |
| 2/2012 | Helicos BioSciences | Series A | 27M |
| 9/2010 | Okairos | Series B | 20.5M |
| 11/2019 | CODA Biotherapeutics | Series A | 15M |
| 3/2013 | Theraclone Sciences | Series B | 0 |
| 9/2008 | ForteBio | Series C | 25M |
| 12/2017 | Jnana Therapeutics | Series A | 50M |
| 5/2003 | Accelerator Corp. | Venture Round | 0 |
| 3/2009 | NeoVista | Series D | 18M |
| 6/2009 | Ocular Therapeutix | Series C | 15M |
| 11/2003 | Saegis Pharmaceuticals | Series B | 30M |
| 7/2008 | Immune Design | Series A | 18M |
| 10/2002 | Insulet | Series C | 22M |
| 9/2020 | Monte Rosa Therapeutics | Series B | 0 |
| 10/2002 | Pharmion | Venture Round | 40M |
| 2/2018 | Quentis | Series A | 48M |
| 12/2019 | Pipeline Therapeutics | Series B | 0 |
| 8/2005 | Amira Pharmaceuticals | Series A | 3M |
| 11/2006 | NewHope Bariatrics | Private Equity Round | 18.5M |
| 4/2006 | MedManage Systems | Series D | 10.8M |
| 4/2021 | Capsida | Series A | 50M |
| 9/2014 | Zyga Technology | Series D | 2M |
| 3/2002 | Phenomix | Series A | 12M |
| 3/2004 | Insulet | Series D | 35.5M |
| 9/2014 | AcuFocus | Venture Round | 0 |
| 11/2018 | Aprea | Series C | 0 |
| 9/2008 | APT Pharmaceuticals | Series B | 32M |
| 10/2003 | Biospect | Series B | 27M |
| 4/2007 | CymaBay Therapeutics | Series D | 32M |
| 6/2004 | Inogen | Series B | 6M |
| 2/2009 | WaveTec Vision | Series C | 20.1M |
| 5/2012 | Zyga Technology | Series C | 25M |
| 5/2011 | WaveTec Vision | Series D | 15.9M |
| 9/2007 | OpGen | Venture Round | 0 |
| 7/2017 | Sebacia | Series D | 0 |
| 10/2006 | Achaogen | Series B | 26M |
| 4/2010 | Groove Biopharma | Series A | 3.9M |
| 7/2010 | Immune Design | Series B | 32M |
| 1/2008 | Confirma | Series C | 0 |
| 10/2005 | ForteBio | Series B | 17.3M |
| 7/2017 | Venatorx Pharmaceuticals | Series B | 42M |
| 9/2001 | Amphora Discovery | Series A | 35M |
| 2/2006 | Insulet Corporation | Series E | 0 |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 2/2013 | Glaukos | Series F | 30M |
| 1/2010 | Intuity Medical | Series D | 64M |
| 5/2007 | WaveTec Vision | Series B | 13M |
| 1/2004 | Intuity Medical | Series B | 0 |
| 6/2021 | LENZ Therapeutics | Series A | 47M |
| 6/2020 | Lycia Therapeutics | Series A | 50M |
| 12/2020 | Gritstone Bio | Post-IPO Equity | 125M |
| 4/2006 | Spiration | Series F | 13.4M |
| 1/2004 | Novacea | Series C | 35M |
| 9/2020 | Graphite Bio | Series A | 45M |
| 11/2002 | Novacea | Series B | 36M |
| 2/2011 | NeoVista | Series E | 33M |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 10/2008 | Respicardia | Series B | 0 |
| 1/2011 | Ocular Therapeutix | Series C | 6M |
| 8/2008 | GluMetrics | Series C | 20.1M |
| 11/2011 | AcuFocus | Private Equity Round | 0 |
| 6/2008 | Cameron Health | Series E | 0 |
| 4/2015 | Twelve | Series C | 35M |
| 4/2008 | Bird Rock Bio | Series A | 8M |
| 4/2013 | RedBrick Health | Private Equity Round | 14M |
| 2/2021 | Pipeline Therapeutics | Series C | 0 |
| 6/2013 | Ocular Therapeutix | Series D | 23.8M |
| 12/2015 | Kyras Therapeutics | Series A | - |
| 2/2011 | Glaukos | Series E | 0 |
| 9/2006 | NeoVista | Series B | 26M |
| 10/2021 | Tentarix Biotherapeutics | Series A | 50M |
| 8/2012 | ForSight VISION5 | Venture Round | 8M |
| 4/2011 | Benvenue Medical | Series C | 35.5M |
| 3/2009 | LensX Lasers | Series B | 22.4M |
| 4/2014 | ForSight VISION5 | Equity | 15M |
| 4/2014 | ForSight Labs | Series C | 15M |
| 4/2015 | CRISPR Therapeutics | Series A | 35M |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 12/2020 | RayzeBio | Series B | 105M |
| 8/2020 | Chinook Therapeutics | Private Placement | 106M |
| 8/2006 | Vantage Oncology | Series C | 0 |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 5/2005 | Vantage Oncology | Series C | 0 |
| 5/2020 | Monte Rosa Therapeutics | Series A | 32.5M |
| 4/2007 | Acclarent | Series C | 35M |
| 6/2021 | Stablix | Series A | 63M |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 6/2004 | Vantage Oncology | Series B | 0 |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 1/2004 | Spiration | Series E | 0 |
| 4/2015 | CRISPR Therapeutics | Series B | 29M |
| 1/2005 | Alexza Pharmaceuticals | Series D | 0 |
| 9/2008 | Microfabrica | Series B | 22.5M |
| 2/2017 | Tarveda Therapeutics | Series D | 30M |
| 11/2001 | ParAllele Bioscience | Series A | - |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 4/2013 | GenSight Biologics | Series A | 41.7M |
| 3/2018 | Tempest Therapeutics | Series B | 70M |
| 11/2016 | Turnstone Biologics | Series B | 0 |
| 7/2021 | Turnstone Biologics | Series D | 0 |
| 5/2018 | Lava Therapeutics | Series A | 18.7M |
| 9/2020 | Lava Therapeutics | Series C | 83M |
| 4/2009 | RedBrick Health | Series C | 15M |
| 5/2009 | Realeve | Series B | 20M |
| 8/2011 | RedBrick Health | Series D | 5M |
| 6/2010 | Veracyte | Series B | 28M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 4/2019 | Vividion Therapeutics | Series B | 82M |
| 1/2007 | AcuFocus | Series D | 0 |
| 1/2013 | GluMetrics | Debt Financing | 5.6M |
| 12/2008 | CELLutions Biosystems | Series B | 8.8M |
| 8/2000 | Syrrx | Series A | 5.1M |
| 6/2017 | Monteris Medical | Series C | 26.6M |
| 12/2007 | RedBrick Health | Series B | 15M |
| 12/2015 | Inception IBD | Series A | 14.1M |
| 3/2016 | Aprea | Series B | 50.6M |
| 11/2002 | Vantage Oncology | Series A | 9M |
| 12/2013 | Inception Sciences | Series A | 10M |
| 5/2001 | CardioNow | Series C | 6M |
| 8/2020 | Matterhorn Biosciences | Venture Round | 30M |
| 11/2009 | Standard BioTools | Venture Round | 0 |
| 5/2008 | Novasys Health | Venture Round | 49.5M |
| 7/2006 | Pathwork Diagnostics | Venture Round | 11M |
| 1/2008 | Benvenue Medical | Series B | 15M |
| 7/2007 | Ablation Frontiers | Series C | 0 |
| 11/2003 | Cameron Health | Series B | 29M |
| 9/2010 | Nuvaira | Series A | 3M |
| 9/2002 | Glaukos | Series A | 10M |
| 12/2016 | BlueRock Therapeutics | Series A | 225M |
| 5/2008 | Novasys Medical, Inc. | Series D | 49.5M |
| 9/2005 | Kythera Biopharmaceuticals | Seed Round | 1M |
| 4/2008 | Anaphore | Venture Round | 8M |
| 1/2009 | Anaphore | Series A | 25M |
| 4/2005 | NovaCardia | Series A | - |
| 6/2012 | Halscion, Inc. | Debt Financing | 4.3M |
| 10/2005 | Cameron Health | Series C | 15M |
| 12/2000 | Confirma | Series B | 12M |
| 9/2006 | NovaCardia | Series B | 48M |
| 6/2004 | Aria Biosystems | Series A | 5.5M |
| 4/2014 | Nuvaira | Series D | 42M |
| 3/2008 | Ocular Therapeutix | Series B | 6M |
| 4/2009 | Ambrx | Series D | 10M |
| 12/2018 | Black Diamond Therapeutics | Series A | 20M |
| 10/2012 | Cotera | Venture Round | 5M |
| 12/2016 | Veran Medical Technologies | Venture Round | 31M |
| 10/2009 | Halscion, Inc. | Venture Round | 6M |
| 9/2003 | ParAllele Bioscience | Series B | 22.5M |
| 1/2004 | Standard BioTools | Series D | 21M |
| 6/2009 | Anaphore | Series A | 13M |
| 9/2019 | Anokion | Series B | 40M |
| 3/2012 | OpGen | Series C | 0 |
| 8/2007 | MedManage Systems | Series E | 5M |
| 6/2023 | Kate Therapeutics | Series A | 0 |
| 1/2007 | Standard BioTools | Series E | 0 |
| 1/2011 | SpaceOAR | Debt Financing | 3M |
| 12/2011 | Groove Biopharma | Series B | 6M |
| 3/2013 | Novira Therapeutics | Series A | 0 |
| 9/2018 | CODA Biotherapeutics | Series A | 19M |
| 11/2001 | Standard BioTools | Series C | 34M |
| 4/2023 | Abdera Therapeutics | Series A | - |
| 1/2023 | Belharra Therapeutics | Series A | 0 |
| 4/2022 | Tempest Therapeutics | Post-IPO Equity | 0 |
| 4/2022 | Cimeio Therapeutics | Series A | 0 |
| 3/2007 | Amira Pharmaceuticals | Series B | 25M |
| 4/2014 | CRISPR Therapeutics | Series A | 25M |
| 5/2010 | Sequent Medical | Series B | 15.6M |
| 10/2020 | VectivBio | Equity | 110M |
| 12/2006 | NeoVista | Series C | 41M |
| 2/2011 | Ocular Therapeutix | Series D | 14M |
| 7/2006 | Cameron Health | Series D | 31M |
| 10/2012 | Cerephex | Series A | 5.9M |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 7/2008 | OraMetrix | Series C | 0 |
| 3/2012 | GluMetrics | Venture Round | 13.3M |
| 11/2011 | Hicuity Health | Series D | 0 |
| 3/2014 | Bird Rock Bio | Series B | 0 |
| 1/2009 | Bird Rock Bio | Series A | 25M |
| 10/2007 | Vital Therapies | Series C | 28.1M |
| 4/2004 | MedManage Systems | Series C | 6M |
| 11/2008 | CodeRyte | Series D | 0 |
| 6/2007 | CELLutions Biosystems | Series B | 7M |
| 1/2017 | Jecure Therapeutics | Series A | 20M |
| 8/2012 | Intuity Medical | Venture Round | 12M |
| 8/2006 | Intuity Medical | Series C | 20M |
| 6/2002 | Intuity Medical | Series A | 3M |
| 4/2004 | ROX Medical | Series A | 3.6M |
| 9/2016 | Rox Medical | Series E | 40M |
| 6/2015 | Inari Medical | Series B | 12.4M |
| 3/2009 | Rennovia | Series A | 16.3M |
| 10/2007 | APT Pharmaceuticals | Series A | 22M |
| 1/2019 | Halio | Series D | 100M |
| 6/2012 | Benvenue Medical | Series D | 25M |
| 6/2014 | Benvenue Medical | Series E | 40M |
| 6/2002 | Salmedix | Series B | 27.5M |
| 1/2009 | Acclarent | Venture Round | 26M |
| 2/2005 | Five Prime Therapeutics | Series C | 45M |
| 8/2019 | Chinook Therapeutics | Series A | 65M |
| 12/2003 | Confirma | Venture Round | 3M |
| 9/2010 | OpGen | Series B | 0 |
| 5/2020 | Ventus Therapeutics | Series A | 60M |
| 6/2012 | Twelve | Series B | 15M |
| 1/2008 | Nexis Vision | Series A | 6M |
| 1/2006 | ForSight Labs | Venture Round | 2.4M |
| 9/2005 | Standard BioTools | Series D | 0 |
| 3/2006 | Helicos BioSciences | Series B | 40M |
| 4/2007 | ForSight Labs | Series A | 5M |
| 4/2008 | SpaceOAR | Series A | 0 |
| 9/2012 | Nuvaira | Series B | 10.6M |
| 1/2004 | Amphora Discovery | Series B | 12.9M |
| 12/2004 | CymaBay Therapeutics | Series B | 44M |
| 1/2018 | Metavention | Series C | 0 |
| 6/2023 | Kate Therapeutics | Series A | 0 |
| 4/2023 | Abdera Therapeutics | Series A | - |
| 1/2023 | Belharra Therapeutics | Series A | 0 |
| 12/2022 | Launchpad Therapeutics | Series A | 0 |
| 11/2022 | iECURE | Series A | 0 |
| 11/2022 | Jnana Therapeutics | Series C | 0 |
| 8/2022 | Vector BioPharma | Series A | 0 |
| 4/2022 | Tempest Therapeutics | Post-IPO Equity | 0 |
| 4/2022 | Cimeio Therapeutics | Series A | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
